Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.

[1]  A. Jankowska,et al.  Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysis , 2010, Genes, chromosomes & cancer.

[2]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[3]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[4]  P. D. Dal Cin,et al.  Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura , 2009, British journal of haematology.

[5]  L. Garçon,et al.  Association between myeloid malignancies and acquired deficit in protein 4.1R: A retrospective analysis of six patients , 2008, American journal of hematology.

[6]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[7]  Raavi Gupta,et al.  Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation , 2007, British journal of haematology.

[8]  P. Fenaux.  Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. , 2004, Seminars in hematology.

[9]  C. Schoch,et al.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.

[10]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[11]  K. Ohyashiki,et al.  Clinico-hematologic Features of Myelodysplastic Syndrome Presenting as Isolated Thrombocytopenia: An Entity with a Relatively Favorable Prognosis , 2003, Leukemia & lymphoma.

[12]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[13]  P. Fenaux,et al.  Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases , 2001, Leukemia.

[14]  T. L. Hood,et al.  Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes , 2000, Oncogene.

[15]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[16]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[17]  E. Wattel,et al.  Low incidence of specific anti‐platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy , 1996, British journal of haematology.

[18]  J. Boultwood,et al.  The 5q-syndrome. , 1994, Blood.

[19]  R. Jenkins,et al.  Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. , 1992, American journal of clinical pathology.

[20]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.